Want to see AU:PTX full AI Analyst Report?
Top Page
Prescient Therapeutics Limited
(Sydney:PTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
AU$0.09
▼(-4.44% Downside)
Action:Reiterated
Date:07/28/26
The score is primarily held back by weak financial performance driven by ongoing losses and persistent negative free cash flow, despite strong revenue growth and low leverage. Technicals are supportive with the stock trading above key moving averages, while valuation is difficult to assess due to negative earnings and no stated dividend yield.
Positive Factors
Revenue Growth (~44% YoY)
Sustained ~44% year-over-year revenue growth signals meaningful commercial or developmental traction for a clinical-stage biotech. Over 2-6 months this trend supports increased partner interest, validates programs, and improves bargaining power for licensing or collaboration deals that fund further development.
Negative Factors
Persistent Structural Losses
Ongoing operating and net losses indicate the company has not reached profitability and will likely rely on external financing. Over a 2-6 month horizon this increases dilution and execution risk, as continued R&D spend must be funded while revenue growth has yet to offset operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth (~44% YoY)
Sustained ~44% year-over-year revenue growth signals meaningful commercial or developmental traction for a clinical-stage biotech. Over 2-6 months this trend supports increased partner interest, validates programs, and improves bargaining power for licensing or collaboration deals that fund further development.
Read all positive factors
Prescient Therapeutics Limited (PTX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$89.38M
Dividend YieldN/A
Average Volume (3M)690.15K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS Growth-13.64%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Prescient Therapeutics Limited Business Overview & Revenue Model
Company Description
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several cl...
How the Company Makes Money
Prescient Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it is not primarily a product-sales business. Its ability to generate revenue is typically expected to come from (i) partnering/licensin...
Prescient Therapeutics Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.11M | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M |
| Gross Profit | 3.11M | 4.36M | 3.71M | 2.43M | 1.89M | 1.19M |
| EBITDA | -10.06M | -7.54M | -7.19M | -7.46M | -6.86M | -5.32M |
| Net Income | -8.86M | -7.32M | -8.24M | -7.00M | -5.12M | -4.15M |
Balance Sheet | ||||||
| Total Assets | 18.48M | 14.56M | 20.39M | 28.11M | 17.62M | 20.97M |
| Cash, Cash Equivalents and Short-Term Investments | 9.77M | 6.93M | 14.51M | 21.92M | 12.28M | 16.12M |
| Total Debt | 495.89K | 0.00 | 330.49K | 0.00 | 0.00 | 165.83K |
| Total Liabilities | 1.51M | 3.17M | 2.33M | 2.03M | 856.01K | 539.68K |
| Stockholders Equity | 16.97M | 11.39M | 18.07M | 26.08M | 16.76M | 20.43M |
Cash Flow | ||||||
| Free Cash Flow | -8.00M | -7.24M | -7.40M | -6.19M | -4.32M | -3.97M |
| Operating Cash Flow | -8.00M | -7.24M | -7.40M | -6.19M | -4.31M | -3.97M |
| Investing Cash Flow | 2.00M | 4.00M | 12.00M | -16.00M | -4.43K | -2.31K |
| Financing Cash Flow | 9.02M | -330.49K | 18.15K | 15.83M | 428.29K | 12.75M |
Prescient Therapeutics Limited Technical Analysis
Positive
0.09
Price Trends
0.07
Positive
0.07
Positive
0.07
Positive
Market Momentum
<0.01
Negative
63.93
Neutral
76.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PTX, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.93 is Neutral, neither overbought nor oversold. The STOCH value of 76.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PTX.
Prescient Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$4.83B | -442.68 | -1.72% | ― | 59.13% | -121.52% | |
54 Neutral | AU$89.38M | -8.42 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$884.20M | -8.46 | -59.59% | ― | ― | -70.72% | |
45 Neutral | AU$55.00M | -0.92 | -93.08% | ― | 116.02% | 75.56% | |
41 Neutral | AU$41.63M | -0.38 | -134.65% | ― | ― | 62.72% | |
40 Underperform | AU$67.79M | -0.80 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:PTX
Prescient Therapeutics Limited
0.09
0.04
100.00%
AU:IMU
Imugene
0.09
-0.18
-67.92%
AU:IMM
Immutep Ltd
0.05
-0.21
-81.54%
AU:TLX
Telix Pharmaceuticals
16.19
-0.70
-4.14%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.69
-1.04
-27.88%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.01
-50.00%
Prescient Therapeutics Limited Corporate Events
Prescient Therapeutics Boosts PTX-100 Trial Momentum and Expands Global Oncology Footprint
Jul 27, 2026
Prescient Therapeutics reported cash and term deposits of $9.03 million at 30 June 2026, up from $7.93 million in March, with quarterly net operating cash outflows of $2.87 million driven largely by $1.80 million in RD and clinical spending, inclu...
Prescient Therapeutics Cleans Up Capital Structure as 4 Million Options Expire
Jul 10, 2026
Prescient Therapeutics Limited has reported the cessation of a tranche of listed options, designated PTXAJ, following their scheduled expiry on 7 July 2026. The expired series comprised 4,000,000 options exercisable at $0.358, which lapsed without...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.